Mabwell (shanghai) Bioscience Co., Ltd. Class ASSE: 688062

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

Sep 2, 2026 · Issued by Mabwell (shanghai) Bioscience Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Mabwell (shanghai) Bioscience Co., Ltd. Class A

"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026Aug 31
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab InjectionsAug 9
"MABWELL (SHANGHAI) BIOSCIENCE CO., LTD."Announcement on Voluntary Disclosure of the Approval by the National Medical Products Administration of the Clinical Trial Application for 9MW5211 InjectionJul 16
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public OfferingJun 26

All Mabwell (shanghai) Bioscience Co., Ltd. Class A news releases